<DOC>
	<DOCNO>NCT00004926</DOCNO>
	<brief_summary>RATIONALE : ILX23-7553 may help solid tumor cell develop normal cell . PURPOSE : Phase I trial study effectiveness ILX23-7553 treating patient solid tumor respond previous therapy .</brief_summary>
	<brief_title>ILX23-7553 Treating Patients With Solid Tumors That Have Not Responded Previous Therapy</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose recommended phase II dose ILX23-7553 patient refractory solid tumor . II . Determine principal dose limit toxicity treatment regimen term duration reversibility patient population . III . Determine preliminary evidence antitumor activity treatment regimen patient . OUTLINE : This dose escalation , multicenter study . Patients receive oral ILX23-7553 5 day . Treatment repeat every 2 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos ILX23-7553 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 2 10 patient experience dose limit toxicity . Patients follow monthly least 2 month . PROJECTED ACCRUAL : A total 46 patient accrue study within 12-18 month .</detailed_description>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Ro 23-7553</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm solid tumor refractory conventional therapy standard therapy exist Measurable evaluable disease PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9.0 g/dL Hepatic : Bilirubin great 2.0 mg/dL ( regardless liver metastasis ) SGOT/SGPT great 2 time upper limit normal Renal : Creatinine great 1.5 mg/dL Calcium great 9.5 mg/dL No nephrocalcinosis Cardiovascular : No congestive heart failure No angina ischemia Other : Ability swallow nasogastric gastrostomy tube present Adequate organ immune system function No known hypersensitivity ILX237553 analogues HIV negative No active uncontrolled infection No severe disease psychiatric disorder would preclude study Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 4 week since prior chemotherapy ( 6 week since nitrosoureas mitomycin ) recover No concurrent curative antineoplastic drug Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy recover No concurrent curative radiotherapy Surgery : At least 4 week since prior surgery recover Other : At least 30 day since prior investigational agent At least 2 week since prior vitamin D , calcium supplementation , cholestyramine No concurrent vitamin D , calcium supplementation , cholestyramine No concurrent digoxin No concurrent hypercalcemia therapy ( i.e. , biphosphonates insulin )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>